MG
IBIO icon

Michael Gelband’s iBio IBIO Stock Holding History

Michael Gelband’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-73
Closed -$39K – 2362
2021
Q3 		$39K Sell
73
-4
-5% -$2.49K ﹤0.01% 1989
2021
Q2 		$58K Buy
+77
New +$56.2K ﹤0.01% 2209
2020
Q2 		– Sell
-79
Closed -$42K – 1884
2020
Q1 		$42K Buy
79
+57
+259% +$21.9K ﹤0.01% 971
2019
Q4 		$3K Buy
+22
New +$2.98K ﹤0.01% 1481

Other funds holding IBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Michael Gelband's IBIO Position: Q4 2021 in Review

Michael Gelband sold out of iBio (IBIO) in Q4 2021, closing a stake of 73 shares — an estimated $39K sold.

Michael Gelband first reported a position in IBIO in Q4 2019 and held it in 4 quarters. The position peaked at $58K in Q2 2021. 77 funds tracked by Wall St. Rank hold IBIO as of Q4 2021.

  • Michael Gelband reported no remaining iBio position as of Q4 2021 after selling out during the quarter.
  • Michael Gelband sold 73 iBio shares in Q4 2021, an estimated $39K.
  • Michael Gelband first reported a position in iBio in Q4 2019 and held it in 4 quarters.
  • Michael Gelband's iBio position peaked at $58K in Q2 2021.
  • 77 funds tracked by Wall St. Rank held iBio as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.